U.S. Approved Medicines
Our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved or authorized medicines, almost all of which were homegrown in Regeneron's laboratories. This page is intended for U.S. residents only.
Medical Inquiries
Healthcare professionals, patients or caregivers may report an adverse event or report a product complaint for a Regeneron product to our Global Medical Information Department. In addition, healthcare professionals may request specific product information. Please call our global phone number +353 61 533 400 or email Medical.information_Global@regeneron.com. For country-specific contact information, refer to our Global Medical Information contact list.
With our commitment to patient safety, if you are reporting an adverse event or product complaint, please report as much relevant information as possible which may include product indication, lot number and return availability.
DUPIXENT® (dupilumab) Injection
EVKEEZA® (evinacumab-dgnb) Injection
EYLEA HD® (aflibercept) Injection
EYLEA® (aflibercept) Injection
INMAZEB® (atoltivimab, maftivimab, and odesivimab-ebgn) Injection
KEVZARA® (sarilumab) Injection
LIBTAYO® (cemiplimab-rwlc) Injection
PRALUENT® (alirocumab) Injection
Veopoz™ (pozelimab-bbfg) Injection
AUTHORIZED FOR EMERGENCY USE ONLY
COVID-19 Treatment Resources
FDA Letter of Authorization for EUA
Fact Sheet for U.S. Healthcare Providers (English)
Our antibody combination is not currently authorized for use in any U.S. region. Please refer to the authorized Fact Sheet and FDA statement for additional details.
Last updated 12/2024
US.REGN.24.09.0001